Last updated on October 2015

Safety and Tolerability of BAY1862864 Injection in Subjects With Relapsed or Refractory CD22-positive Non-Hodgkin's Lymphoma


Brief description of study

To establish a recommended dose of BAY1862864 Injection and to investigate how the study drug acts in the body, on the cancer cells and how safe it is in patients with advanced non-Hodgkin's lymphoma (NHL)

Detailed Study Description

The study will be divided into two parts: a "dose-escalation part" to evaluate safety profile and to explore the Maximum tolerated dose (MTD) and an "expansion part" to evaluate further the safety and tumor response profile of BAY1862864 Injection at the selected dose.

Clinical Study Identifier: NCT02581878

Contact Investigators or Research Sites near you

Start Over

Bayer Clinical Trials Contact

Allgemeines Krankenhaus der Stadt Wien
Wien, Austria
  Connect »

Bayer Clinical Trials Contact

Universit tsklinikum Heidelberg
Heidelberg, Germany
  Connect »

Bayer Clinical Trials Contact

Klinikum rechts der Isar
München, Germany
  Connect »

Bayer Clinical Trials Contact

Sk nes Universitetssjukhus
Lund, Sweden
  Connect »

Bayer Clinical Trials Contact

Southampton General Hospital
Southampton, United Kingdom
  Connect »

Bayer Clinical Trials Contact

Royal Marsden NHS Trust (Surrey)
Sutton, United Kingdom
  Connect »

Bayer Clinical Trials Contact

Royal Free Hospital
London, United Kingdom
  Connect »